Loading chat...
KS HB2157
Bill
Status
1/29/2025
Primary Sponsor
Health and Human Services
Click for details
AI Summary
-
Adds COVID-19 to the list of health conditions pharmacists may test for and treat under statewide protocols, joining influenza, streptococcal pharyngitis, and urinary tract infections
-
Requires the collaborative drug therapy management advisory committee to establish statewide protocols specifying approved medications, pharmacist training requirements, documentation standards, and patient communication requirements
-
Authorizes the Board of Pharmacy to deny, revoke, or suspend a pharmacist's license for violating these provisions or failing to follow established protocols
-
Amends K.S.A. 2024 Supp. 65-16,131 and takes effect upon publication in the statute book
Legislative Description
Expanding pharmacist's scope of practice to include point-of-care testing for and treatment of COVID-19.
Last Action
House Withdrawn from Committee on Health and Human Services; Referred to Committee on Insurance
3/13/2026